Company: Tivorsan Pharmaceuticals
Location: US-Rhode Island
Drug Type: Protein Biologic
Conditions: ALS, Duchenne muscular dystrophy (DMD)
Mechanism Type: NMJ stabilization
Mechanism: Recombinant biglycan (TVN-102) aims to stabilize neuromuscular junctions by increasing MuSK activation. The approach is based on previous studies which found that biglycan stabilizes these synapses in part, by regulating the localization and levels of MuSK at motor nerve terminals (Amenta et al., 2012).
U.S. Status for ALS: Preclinical
 Biglycan is an extracellular MuSK binding protein important for synapse stability. Amenta, AR et al. J Neurosci. 2012 Feb 15;32(7):2324-34.
 Tivorsan Pharmaceuticals Closes Private Placement. Business Wire, 5 Feb 2016. Accessed 11 Mar 2016 from http://www.businesswire.com/news/home/20160205005030/en/Tivorsan-Pharmaceuticals-Closes-Private-Placement.
Last updated June 22nd, 2017